Acadia's recent presentation at the TD Cowen conference is worth a listen. Provides some good insights into the European expansion strategy. Will no doubt be some challenges to the roll out due to the different jurisdictions and the UK sounds like a maybe at best for now. However, Acadia is well on the front foot with this and the enthusiasm for the drug sounds extremely high so the Managed Access programs are eagerly anticipated. Worth remembering too that the annual guidance is just the US only so any revenue outside that is all upside.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.100(0.80%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.44 | $12.73 | $12.13 | $11.07M | 885.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1215 | $12.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.54 | 804 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |